Penis Enlargement

Abstract

A method for causing a permanent increase in the length and girth of a male subject's penis, the method comprising treatment comprising the step of (a) administering to the male an effective amount of a vasodilator selected from the group consisting of a vasodilator per se and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause the increase during the treatment. A potentiator which enhances the effect of the vasodilator may also be used.

1 . A method for causing, a permanent increase in the length and girth of a male subject's penis, said method comprising treatment comprising the step of (a) administering to said male an effective amount of a vasodilator and a potentiator for said vasodilator to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause said permanent increase during said treatment. 
   
   
       2 . A method as defined in  claim 1 , wherein said vasodilator is in admixture with a pharmaceutically-acceptable diluent or carrier, 
   
   
       3 . (canceled) 
   
   
       4 . A method as defined in  claim 1 , wherein said prolonged engorgement is sustained for at least 4 hours. 
   
   
       5 . A method as defined in  claim 1 , wherein said vasodilator is administered as one dose in said treatment step throughout the prolonged engorgement. 
   
   
       6 . A method as defined in  claim 1 , wherein said vasodilator is administered as at least two doses as defined in said treatment throughout the prolonged engorgement. 
   
   
       7 . A method as defined in  claim 6 , wherein the engorgement comprises a first erectile response of at least 65%, and a second dose or subsequent doses are administered after the first erectile response falls below 65% during said treatment. 
   
   
       8 . (canceled) 
   
   
       9 . A method as defined in  claim 1 , wherein said treatment is applied to said patient at least four times per week for a period of at least 3 months. 
   
   
       10 . A method as defined in  claim 1 , wherein the length of the fully erect penis has increased by at least 5% after a treatment period of 12 to 18 months. 
   
   
       11 . A method as defined in  claim 10 , wherein the length of the fully erect penis is increased by at least 30% after a treatment period of 12 to 18 months. 
   
   
       12 . A method as defined in  claim 1 , wherein the girth of the fully erect penis is increased by at least 5% after a treatment period of 12 to 18 months. 
   
   
       13 . A method as defined in  claim 12 , wherein the girth of the fully erect penis is increased by at least 30% after a treatment period of 12 to 18 months. 
   
   
       14 . A method as defined in  claim 1 , wherein said engorgement comprises a 75-100% erectile response for at least 90% of the time of the prolonged engorgement. 
   
   
       15 . A method as defined in  claim 1 , wherein said engorgement comprises a 75-100% erectile response for 50-90% of the time of the prolonged engorgement. 
   
   
       16 . A method as defined in  claim 1 , wherein said engorgement comprises a 75-100% erectile response for up to 50% of the time of the prolonged engorgement. 
   
   
       17 . A method as defined in  claim 1 , wherein said engorgement comprises a 40-75% erectile response for at least 3 hours. 
   
   
       18 . A method as defined in  claim 1 , wherein said vasodilator is selected from the group consisting of nitrovasodilators, ACE inhibitors, angiotensin receptor antagonists, phosphodiesterase inhibitors, direct vasodilators, adrenergic receptor antagonists, calcium channel blocking drugs, alpha blockers, beta blockers, lymphthomimetics, vitamins, organic nitrates, serotonin receptorblocking agents, angina blocking agents, other hypertensive agents, cardiac stimulating agents, agents which improve renal, vascular function, sympathomimetic amine, and salts, derivatives precursors, pharmaceutically active sequences or regions, peptidomimetics, mimetics, and mixtures thereof. 
   
   
       19 . A method as defined in  claim 18 , wherein said vasodilator is selected from the group consisting of papaverine, chlorpromazine, atropine, phentolamine, and prostaglandin E1, or a mixture thereof. 
   
   
       20 . A method as defined in  claim 19 , wherein said vasodilator is prostaglandin E1. 
   
   
       21 . A method as defined in  claim 1 , wherein said vasodilator is formulated for administration by direct injection to the cavernosal tissue, by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, urethral suppository, or implantable sustained release drug or device. 
   
   
       22 . A method as defined in  claim 1 , wherein said vasodilator is formulated for systemic administration by oral, sublingual, or suppository administration, intravenous administration by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, or implantable sustained release drug or device, or topical administration, such as through the use of creams, lotions or patches. 
   
   
       23 . A method as defined in  claim 1 , wherein said vasodilator is administered to the dense connective tissue surrounding the erectile tissue of the penis by a deep injection that goes below the dermis and subcutaneous tissues. 
   
   
       24 . A method as defined in  claim 1 , wherein said vasodilator is administered to the dorsal suspensory ligand of the penis. 
   
   
       25 . A method as defined in  claim 1 , wherein said vasodilator is administered as an intracavemosal injection. 
   
   
       26 . A method as defined in  claim 21 , wherein said vasodilator is administered as an implantable sustained release drug or device. 
   
   
       27 . A method as defined in  claim 20 , wherein said prostaglandin El is administered at a dosage of 0.5 to 100 micrograms/kg body weight/day by intracavemosal injection. 
   
   
       28 . A method as defined in  claim 20 , wherein the prostaglandin El is administered systemically at a dosage of 2 to 10,000 microgramslkg body weight/day by an implantable sustained release drug or device. 
   
   
       29 . (canceled) 
   
   
       30 . A method as defined in  claim 1 , wherein the potentiator is administered by direct injection to the cavernosal tissue, by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, urethral suppository, or implantable sustained release drug or device. 
   
   
       31 . A method as defined in  claim 1 , wherein the potentiator is systemically administered by oral, sublingual, or suppository administration, intravenous administration by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, or implantable sustained release drug or device, or topical administration, such as through the use of creams, lotions or patches. 
   
   
       32 . A method as defined in  claim 1 , wherein the potentiator is administered to the dense connective tissue surrounding the erectile tissue of the penis by a deep injection that is well below the dermis and subcutaneous tissues. 
   
   
       33 . A method as defined in  claim 1 , wherein the potentiator is administered to the dorsal suspensory ligand of the penis. 
   
   
       34 . A method as defined in  claim 1 , wherein the potentiator is administered by intracavemosal injection. 
   
   
       35 . A method as defined in  claim 1 , wherein the potentiator is administered as an implantable sustained release drug or device. 
   
   
       36 . A method as defined in  claim 1 , wherein the potentiator is administered separately from the composition. 
   
   
       37 . A method as defined in  claim 1 , wherein the potentiator is administered concurrently with the composition. 
   
   
       38 . A method as defined in  claim 1 , wherein the potentiator is administered more than once during said treatment. 
   
   
       39 . A method as defined in  claim 1  wherein the potentiator is a hormone. 
   
   
       40 . A method as defined in  claim 39 , wherein the hormone is an androgen selected 15 from the group consisting of the naturally occurring androgens and derivatives thereof, or an agent that will stimulate the androgen receptor directly or indirectly, including androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol-3-acetate, androstenediol-17-acetate, androstenediol-3, 17-diacetate, androstenediol-17-20 benzoate, androstenediol-3-acetate-17-benzoate, androstenedione, dehydroepiandrosterone (DHEA; also termed “prasterone”), sodium dehydroepiandrosterone sulfate, 4-dihydrotestosterone (DHT; also termed “stanolone”), 17.beta.-hydroxyandrost-4-en-3-one, 5.alpha.-dihydrotestosterone, dromostanolone, dromostanolone propionate, 25 ethylestrenol, nandrolone phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexanepropionate, nandrolone benzoate, nanodrolone cyclohexanecarboxylate, oxandrolone, stanozolol and testosterone, pharmaceutically acceptable esters of testosterone and 4-dihydrotestosterone, including esters formed from the hydroxyl group present at the C-17 position, including, but not limited to, the enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate, buciclate, cyclopentylpropionate, isocarponate, heptanoate, decanoate, undecanoate, caprate and isocaprate esters, pharmaceutically acceptable derivatives of testosterone such as methyl testosterone, testolactone, oxymetholone and fluoxymesterone; synthetic androgens, and 7-Methyl-Nortestosterone (“MENT″”) and its acetate ester, and salts, derivatives, precursors, pharmaceutically active sequences or regions, peptidomimetics, mimetics, and mixtures thereof. 
   
   
       41 . A method as defined in  claim 40 , wherein the androgen is testosterone. 
   
   
       42 . A method as defined in  claim 40 , wherein the androgen is dihydrotestosterone. 
   
   
       43 . A method as defined in  claim 1 , wherein the potentiator promotes the elongation of collagen. 
   
   
       44 . A method as defined in  claim 1 , wherein the potentiator inhibits collagen cross-linkage. 
   
   
       45 . A method as defined in  claim 1 , wherein the potentiator is selected from a group consisting of insulin like growth factor, growth hormone, metallo-porteinases or metallo-proteinase agonists or promoters of collagenase activity, tissue inhibitors of matrix metalloprotenases (TIMPS) other agents that increase collagen solubility, prostaglandins, corticosteroids, potassium aminobenzoate, and dimethyl sulfoxide (DMSO), D-penicillamine, and salts, derivatives, precursors, pharmaceutically active sequences or regions, peptidomimetics, mimetics, and mixtures thereof. 
   
   
       46 . (canceled) 
   
   
       47 . A method as defined in  claim 45 , wherein the prostaglandin is selected from prostaglandin F2 alpha and prostaglandin E2. 
   
   
       48 . A method as defined in  claim 45 , wherein the potentiator is relaxin, prostaglandin F2 alpha, or prostaglandin E2, or the biochemical mediator that results in the desired changes in collagen or the connective tissue that produces and remodels collagen and express the effects of relaxin, prostaglandin F2 alphs, or prostaglandin E2. 
   
   
       49 . A method as defined in  claim 45 , wherein the potentiator is potassium aminobenzoate. 
   
   
       50 . A method as defined in  claim 45 , wherein the potentiator is dimetnyl sulfoxide (DMSO). 
   
   
       51 . A method as defined in  claim 45 , wherein relaxin is administered at a dosage of 0.02 to 1 micrograms/kg body weight/day by intracaversonal injection. 
   
   
       52 . A method as defined in  claim 45 , wherein relaxin is topically administered at a dosage of 25 to 400 micrograms/kg body weight/day. 
   
   
       53 . A method as defined in  claim 45 , wherein relaxin is administered at a dosage of 0.02 to 1 micrograms/kg body weight/day by injection into the dense connective tissue of the erectile tissue surrounding the penis. 
   
   
       54 . A method as defined in  claim 1 , comprising applying a device to prolong the retention of the composition in the penis. 
   
   
       55 . A method as defined in  claim 54 , comprising fitting said device in the form of a ring around the base of the penis. 
   
   
       56 . A kit comprising a vasodilator per se or a composition thereof in admixture with a pharmaceutically-acceptable diluent or carrier, and instructions for administering said vasodilator to a human male according to a method as defined in  claim 1 . 
   
   
       57 . A kit as defined in  claim 56 , wherein the instructions are provided in written form. 
   
   
       58 . A kit as defined in  claim 56  for use wherein the instructions are provided orally by a health professional. 
   
   
       59 . A kit as defined in  claim 56 , wherein the instructions are provided in video compact disc form. 
   
   
       60 . A kit as defined in  claim 56 , further comprising a potentiator for enhancing the effect of the vasodilator. 
   
   
       61 . A kit as defined in  claim 57 , further comprising a potentiator for enhancing the effect of the vasodilator. 
   
   
       62 . A kit as defined in  claim 58 , further comprising a potentiator for enhancing the effect of the vasodilator. 
   
   
       63 . A kit as defined in  claim 59 , further comprising a potentiator for enhancing the effect of the vasodilator. 
   
   
       64 . A method as defined in  claim 19  wherein the potentiator is a hormone. 
   
   
       65 . A method as defined in  claim 1  wherein the vasodilator is prostaglandin E1, papavarine, phentolamine, atropine or chlorpromazine and the potentiator is testosterone, dihydrotestosterone, prostaglandin F, potassium aminobenzoate or dimethyl sulfoxide.